Aemetis, Inc. (NASDAQ:AMTX) Shares Sold by Captrust Financial Advisors

Captrust Financial Advisors reduced its position in shares of Aemetis, Inc. (NASDAQ:AMTX) by 39.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,880 shares of the specialty chemicals company’s stock after selling 47,276 shares during the period. Captrust Financial Advisors owned about 0.14% of Aemetis worth $199,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AMTX. Jane Street Group LLC lifted its position in shares of Aemetis by 1,130.0% during the fourth quarter. Jane Street Group LLC now owns 374,016 shares of the specialty chemicals company’s stock worth $1,006,000 after purchasing an additional 343,609 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Aemetis by 515.9% in the fourth quarter. JPMorgan Chase & Co. now owns 120,716 shares of the specialty chemicals company’s stock worth $325,000 after buying an additional 101,116 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in shares of Aemetis in the fourth quarter worth $227,000. Renaissance Technologies LLC bought a new stake in shares of Aemetis in the fourth quarter worth $203,000. Finally, Russell Investments Group Ltd. increased its stake in shares of Aemetis by 684.5% in the fourth quarter. Russell Investments Group Ltd. now owns 78,191 shares of the specialty chemicals company’s stock worth $210,000 after buying an additional 68,224 shares during the last quarter. 27.02% of the stock is owned by institutional investors and hedge funds.

Aemetis Price Performance

AMTX stock opened at $1.75 on Friday. Aemetis, Inc. has a 1-year low of $1.22 and a 1-year high of $4.73. The firm has a fifty day moving average price of $1.58 and a two-hundred day moving average price of $2.32. The firm has a market cap of $96.90 million, a price-to-earnings ratio of -0.77 and a beta of 1.47.

Aemetis (NASDAQ:AMTX) last released its earnings results on Thursday, May 8th. The specialty chemicals company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.08). The business had revenue of $42.89 million for the quarter, compared to analysts’ expectations of $59.35 million. During the same period last year, the firm posted ($0.58) EPS. As a group, analysts expect that Aemetis, Inc. will post -2.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Ascendiant Capital Markets lifted their price target on shares of Aemetis from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, March 17th. HC Wainwright restated a “buy” rating and issued a $28.00 price target on shares of Aemetis in a research note on Friday, March 14th. UBS Group dropped their price target on shares of Aemetis from $2.50 to $2.20 and set a “buy” rating for the company in a research note on Friday, May 9th. Finally, Wall Street Zen upgraded shares of Aemetis to a “sell” rating in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $13.18.

Aemetis Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.